Importantly, compound 12 showed relatively good bioavailability (F = 38.80%, which is better than our previous report) and low toxicity in vivo. It is of great significance for the discovery of more efficient CDK8 inhibitors and the development of drugs for treating AML. This evidence concerns the gene CDK8 and acute myeloid leukemia.